+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Do low titers of antibody against hepatitis B surface antigen carry a risk of viral reactivation during immunosuppressive therapy for rheumatic diseases?



Do low titers of antibody against hepatitis B surface antigen carry a risk of viral reactivation during immunosuppressive therapy for rheumatic diseases?



Journal of Rheumatology 39(6): 1292-3; Author Reply 1293




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052678681

Download citation: RISBibTeXText

PMID: 22661417

DOI: 10.3899/jrheum.120052


Related references

Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in Hepatitis B surface antigen-negative cases. Journal of Rheumatology 38(10): 2209-2214, 2012

Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: a prospective cohort study. Arthritis Research and Therapy 20(1): 246, 2018

Patients with Coexistence of Circulating Hepatitis B Surface Antigen and Its Antibody May Have a Strong Predisposition to Virus Reactivation During Immunosuppressive Therapy: A Hypothesis. Medical Science Monitor 23: 5980-5985, 2018

Reactivation of hepatitis B virus with mutated hepatitis B surface antigen in a liver transplant recipient receiving a graft from an antibody to hepatitis B surface antigen- and antibody to hepatitis B core antigen-positive donor. Transfusion 52(9): 1999-2006, 2012

Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Annals of the Rheumatic Diseases 65(8): 983-989, 2006

Prophylaxis of hepatitis B reactivation with immunosuppressive therapy in rheumatic diseases. Orientations for clinical practice. Acta Reumatologica Portuguesa 36(2): 110-118, 2011

Risk of hepatitis B virus reactivation in patients who are hepatitis B surface antigen negative/antibody to hepatitis B core antigen positive and the role of routine antiviral prophylaxis. Journal of Clinical Oncology 27(15): 2570-1; Author Reply 2571-2, 2009

Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 100(2): 391-396, 2002

Correlation of the e antigen antibody system with intra hepato cellular hepatitis b core antigen and hepatitis b surface antigen in hepatitis b surface antigen positive acute and chronic liver diseases and healthy hepatitis b surface antigen carriers. Digestion 14(5/6): 488, 1976

Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy--a report of long-term follow-up of serial cases and literature review. Clinical Rheumatology 33(4): 577-586, 2015

Risk of hepatitis B reactivation in hepatitis B surface antigen seronegative and core antibody seropositive kidney transplant recipients. Transplant Infectious Disease 2018: E13009, 2018

Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 51(6): 1933-1944, 2010

Correlations Among Serum Hepatitis B Surface Antigen and Hepatitis B e Antigen Titers and Viral Load in Chinese Patients with Chronic Hepatitis B. Clinical Laboratory 61(5-6): 505-512, 2015

Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Annals of Hematology 90(10): 1219-1223, 2011

Discontinuation of immunosuppressive therapy in hepatitis B surface antigen-positive chronic hepatitis: effect on viral replication and on liver cell damage. Digestion 36(1): 47-54, 1987